Chronotype,eveningness,internet addiction,social media addiction,smart- phone addiction

The primary aim of the current study was to examine the frequency of food addiction in a group of university students and whether it differed among chronotypes. The second aim was to investigate the relationship of chronotypes with impulsivity, poor sleep quality and attention deficit/ hyperactivity disorder (ADHD) symptoms and to evaluate how this relationship affects food addiction. 328 university students were included in the study. Adult Attention Deficit/Hyperactivity Disorder Self-Report Scale (ASRS), Morningness-Eveningness Questionnaire (MEQ), Barratt Impulsiveness Scale-11 Short Form (BIS-11-SF), Yale Food Addiction Scale (YFAS) and Pittsburgh Sleep Quality Index (PSQI) were administered. Evening types scored significantly higher on ASRS and BIS-11 SF (p < .001, p < .001 respectively). Based on YFAS scores, 12.5% (n = 41) of the participants met the criteria for food addiction. The number of participants fulfilling the criteria for food addiction was higher among the evening types compared to intermediate and morning types (p = .006, p = .004, respectively). The mean ASRS and BIS-11 SF scores of the students who met the criteria for food addiction were significantly greater than those who did not (p < .001, p < .001, respectively). 63.4% (n = 26) of the students meeting the criteria for food addiction scored 6 or higher on PSQI versus 32.0% (n = 92) of the students who did not (p < .001). Mediation analysis showed that the direct effect of MEQ scores on food addiction was not significant (β = −0.009, p = .723). However, lower MEQ scores had an indirect effect on food addiction through higher ASRS scores (β = −0.027; p < .05 bias corrected and accelerated 95% CI −0.052 to −0.011). The results of the present study suggest that higher prevalence of food addiction among evening types seems to be related to higher occurrence of ADHD symptoms in these chronotypes. Further population-based studies with a larger sample size are needed to confirm our findings.

Restless legs syndrome,depression,anxiety,antidepressants,selective serotonin reuptake inhibitor

Many case reports have demonstrated that using antidepressants and especially the selective serotonin reuptake inhibitors (SSRIs), and the noradrenergic and specific serotonergic antidepresants mirtazapine and mianserin can lead to restless legs syndrome (RLS). However, there are disagreements in the results of the limited number of investigations on the relationship of RLS with antidepressants. Trazodone is a frequently used antidepressant with complex agonistic/antagonistic effects on the serotonergic system and moderate blockage on the histamine receptor. This report dicusses the case of a 39-year old female patient who developed RLS after using trazodone (100mg/day) prescribed by her pscyhiatrist for treating her insomnia complaints. We have learned from the patient's statement that she felt burning, tingling and restlessness in her legs, that started from the first night of the treatment and caused an urge to move her legs. The effects were attributed to trazodone and the treatment was discontinued. The patient reported at her control examination the disappearance of RLS symptoms one day after discontinuing trazodone use and the complete improvement of her insomnia complaints.

Many case reports have shown that the use of antidepressants can lead to restless legs syndrome (RLS). Vortioxetine is a new generation antidepressant with a multimodal mechanism of action on serotonin receptors. In this case report, partial improvement in RLS symptoms after treatment with vortioxetine in a patient with a co-diagnosis of major depressive disorder and restless legs syndrome will be discussed. A 59-year-old female patient was admitted to the psychiatry outpatient clinic due to depressive complaints for three months. In the control examination, it was learned that the patient had complaints of RLS that had been going on for about 20 years. RLS symptoms were increased with selective serotonin reuptake inhibitors (SSRI) used by the patient. In the follow-up examination in the first month after vortioxetine treatment, clinically significant improvement was observed in the patient's depressive complaints, while a partial reduction in RLS symptoms was observed.

The study investigated associations between chronotypes (Morning [M], Neither [N], Evening [E]), sociodemographic characteristics, body mass index (BMI), smoking habits, years with migraines, sleep quality (PSQI), anxiety (HADS-A), depression (HADS-D), migraine disability (MIDAS), headache frequency, and pain intensity (VAS) in 80 individuals with migraine. Significant age differences emerged (p < 0.001), with M-types being the oldest. BMI also varied, with M-types presenting the highest median BMI (p = 0.005). While migraine duration and headache frequency showed no significant variance, sleep quality did, with E-types reporting the poorest sleep (p = 0.030). Anxiety and depression were significantly worse in E-types (HADS-A: p = 0.002; HADS-D: p = 0.010). Differences in MIDAS levels were notable (p = 0.038); however, differences in MIDAS scores were not significant (p = 0.115). Pain intensity varied, with E-types experiencing the most severe pain (p = 0.009). Post-hoc analysis showed higher MIDAS scores in E-types compared to N-types (χ² = 6.56, p = 0.038, ε² = 0.0831). The findings highlight the need for thorough patient evaluations and tailored care, considering the complex interplay of factors affecting migraine severity, particularly among different chronotypes.